p53: Protection against tumor growth beyond effects on cell cycle and apoptosis

Cancer Research

Volumn 75, Issue 23, 2015, Pages 5001-5007

  Wang, Xuyi ^a,b   Simpson, Evan R ^a,b   Brown, Kristy A ^a,b  

^a HUDSON INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE; AROMATASE INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; ESTROGEN; FORMESTANE; FULVESTRANT; LETROZOLE; NSC 745104; P 28; PEPTIDE INHIBITOR; PROSTAGLANDIN E2; PROTEIN P53; TAMOXIFEN; UNCLASSIFIED DRUG;

ADIPOSE TISSUE; APOPTOSIS; BREAST CANCER; BREAST TUMOR; CANCER GROWTH; CELL CYCLE ARREST; DNA DAMAGE; DRUG TARGETING; ENZYME REGULATION; ESTROGEN SYNTHESIS; GENE MUTATION; GENE SILENCING; HUMAN; METABOLISM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; STROMA; TUMOR GROWTH; TUMOR MICROENVIRONMENT; ANIMAL; CELL CYCLE; NEOPLASM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; APOPTOSIS; CELL CYCLE; HUMANS; NEOPLASMS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84955461060     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-0563     Document Type: Review

References (67)

1. Vousden KH, Lu X. Live or let die: the cell's response to p53. Nat Rev Cancer 2002;2:594-604.
2. Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature 2000;408:307-10.
3. Coutant C, Rouzier R, Qi Y, Lehmann-Che J, Bianchini G, Iwamoto T, et al. Distinct p53 gene signatures are needed to predict prognosis and response to chemotherapy in ER-positive and ER-negative breast cancers. Clin Cancer Res 2011;17:2591-601.
4. Bouvard V, Zaitchouk T, Vacher M, Duthu A, Canivet M, Choisy-Rossi C, et al. Tissue and cell-specific expression of the p53-target genes: bax, fas, mdm2 and waf1/p21, before and following ionising irradiation in mice. Oncogene 2000;19:649-60.
5. Nakano K, Vousden KH. PUMA, a novel proapoptotic gene, is induced by p53. Mol Cell 2001;7:683-94.
6. Bailey ST, Shin H, Westerling T, Liu XS, Brown M. Estrogen receptor prevents p53-dependent apoptosis in breast cancer. Proc Natl Acad Sci U S A 2012;109:18060-5.
7. Rowan S, Ludwig RL, Haupt Y, Bates S, Lu X, Oren M, et al. Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. EMBO J 1996;15:827-38.
8. el-Deiry WS. Regulation of p53 downstream genes. Semin Cancer Biol 1998;8:345-57.
9. Vousden KH, Prives C. Blinded by the light: the growing complexity of p53. Cell 2009;137:413-31.
10. Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 1993;75:805-16.
11. Stewart ZA, Pietenpol JA. p53 Signaling and cell cycle checkpoints. Chem Res Toxicol 2001;14:243-63.
12. Schwartzenberg-Bar-Yoseph F, Armoni M, Karnieli E. The tumor suppressor p53 down-regulates glucose transporters GLUT1 and GLUT4 gene expression. Cancer Res 2004;64:2627-33.
13. Jones RG, Plas DR, Kubek S, Buzzai M, Mu J, Xu Y, et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol cell 2005;18:283-93.
14. Assaily W, Rubinger DA, Wheaton K, Lin Y, Ma W, Xuan W, et al. ROSmediated p53 induction of Lpin1 regulates fatty acid oxidation in response to nutritional stress. Mol cell 2011;44:491-501.
15. Liu Y, He Y, Jin A, Tikunov AP, Zhou L, Tollini LA, et al. Ribosomal protein-Mdm2-p53 pathway coordinates nutrient stress with lipid metabolism by regulating MCD and promoting fatty acid oxidation. Proc Natl Acad Sci U S A 2014;111:E2414-22.
16. Moore T, Beltran L, Carbajal S, Strom S, Traag J, Hursting SD, et al. Dietary energy balance modulates signaling through the Akt/mammalian target of rapamycin pathways in multiple epithelial tissues. Cancer Prev Res 2008;1:65-76.
17. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
18. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB. The biology of cancer: metabolic reprogramming fuels cell growth and proliferation. Cell Metab 2008;7:11-20.
19. Madan E, Gogna R, Bhatt M, Pati U, Kuppusamy P, Mahdi AA. Regulation of glucose metabolism by p53: emerging new roles for the tumor suppressor. Oncotarget 2011;2:948-57.
20. Wu W, Zhao S. Metabolic changes in cancer: beyond the Warburg effect. Acta Biochim Biophys Sin 2013;45:18-26.
21. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
22. Björntorp P. Adipose tissue distribution and function. Int J Obes 1991;15:67-81.
23. Baglietto L, English DR, Hopper JL, MacInnis RJ, Morris HA, Tilley WD, et al. Circulating steroid hormone concentrations in postmenopausal women in relation to body size and composition. Breast Cancer Res Treat 2009;115:171-9.
24. Subbaramaiah K, Howe LR, Bhardwaj P, Du B, Gravaghi C, Yantiss RK, et al. Obesity is associated with inflammation and elevated aromatase expression in the mouse mammary gland. Cancer Prev Res (Phila) 2011;4:329-46.
25. Subbaramaiah K, Morris PG, Zhou XK, Morrow M, Du B, Giri D, et al. Increased levels of COX-2 and prostaglandin E2 contribute to elevated aromatase expression in inflamed breast tissue of obese women. Cancer Discov 2012;2:356-65.
26. Hursting SD, Hursting MJ. Growth signals, inflammation, and vascular perturbations: mechanistic links between obesity, metabolic syndrome, and cancer. Arterioscler Thromb Vasc Biol 2012;32:1766-70.
27. Liu E, Samad F, Mueller BM. Local adipocytes enable estrogen-dependent breast cancer growth: Role of leptin and aromatase. Adipocyte 2013;2:165-9.
28. Vachon CM, Sasano H, Ghosh K, Brandt KR, Watson DA, Reynolds C, et al. Aromatase immunoreactivity is increased in mammographically dense regions of the breast. Breast Cancer Res Treat 2011;125:243-52.
29. Zhao Y, Agarwal VR, Mendelson CR, Simpson ER. Estrogen biosynthesis proximaltoabreast tumor is stimulated by PGE2 via cyclic AMP, leading to activation of promoter II of the CYP19 (aromatase) gene. Endocrinology 1996;137:5739-42.
30. Brown KA, McInnes KJ, Hunger NI, Oakhill JS, Steinberg GR, Simpson ER. Subcellular localization of cyclic AMP-responsive element binding proteinregulated transcription coactivator 2 provides a link between obesity and breast cancer in postmenopausal women. Cancer Res 2009;69:5392-9.
31. Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005;121:335-48.
32. Angelucci C, Maulucci G, Lama G, Proietti G, Colabianchi A, Papi M, et al. Epithelial-stromal interactions in human breast cancer: effects on adhesion, plasma membrane fluidity and migration speed and directness. PLoS One 2012;7:e50804.
33. Li FP, Fraumeni JF Jr. Soft-tissue sarcomas, breast cancer, and other neoplasms. A familial syndrome? Ann Intern Med 1969;71:747-52.
34. Gonzalez KD, Noltner KA, Buzin CH, Gu D, Wen-Fong CY, Nguyen VQ, et al. Beyond Li Fraumeni Syndrome: clinical characteristics offamilies with p53 germline mutations. J Clin Oncol 2009;27:1250-6.
35. Pantziarka P. Li Fraumeni syndrome, cancer and senescence: a new hypothesis. Cancer Cell Int 2013;13:35.
36. Masciari S, Dillon DA, Rath M, Robson M, Weitzel JN, Balmana J, et al. Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effort. Breast Cancer Res Treat 2012; 133:1125-30.
37. Moll UM, Riou G, Levine AJ. Two distinct mechanisms alter p53 in breast cancer: mutation and nuclear exclusion. Proc Natl Acad Sci USA 1992;89:7262-6.
38. Molinari AM, Bontempo P, Schiavone EM, Tortora V, Verdicchio MA, Napolitano M, et al. Estradiol induces functional inactivation of p53 by intracellular redistribution. Cancer Res 2000;60:2594-7.
39. Gu B, Zhu WG. Surf the post-translational modification network of p53 regulation. Int J Biol Sci 2012;8:672-84.
40. 0-AMP activated protein kinase activator, 5-aminoimidazole - 4-carboxamide-1-beta-D-ribofuranoside, in a human hepatocellular carcinoma cell line. Biochem Biophys Res Commun 2001;287:562-7.
41. Choi HK, Roh SH, Kim HG, Han EH, Jeong HG, Kang KW. Enhanced expression of aromatase in p53-inactivated mammary epithelial cells. Endocr Relat Cancer 2008;15:139-47.
42. Gostissa M, Hofmann TG, Will H, Del Sal G. Regulation of p53 functions: let's meet at the nuclear bodies. Curr Opin Cell Biol 2003;15:351-7.
43. Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z, et al. Invivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science (New York, NY) 2004;303:844-8.
44. Wang X, Docanto MM, Sasano H, Lo C, Simpson ER, Brown KA. Prostaglandin E2 inhibits p53 in human breast adipose stromal cells: a novel mechanism for the regulation of aromatase in obesity and breast cancer. Cancer Res 2015;75:645-55.
45. Momand J, Wu HH, Dasgupta G. MDM2-master regulator of the p53 tumor suppressor protein. Gene 2000;242:15-29.
46. Zhou D, Zhou C, Chen S. Gene regulation studies of aromatase expression in breast cancer and adipose stromal cells. J Steroid Biochem Mol Biol 1997;61:273-80.
47. James FR, Wootton S, Jackson A, Wiseman M, Copson ER, Cutress RI. Obesity in breast cancer - What is the risk factor? Eur J Cancer 2015; 51:705-20.
48. Eichholzer M, Richard A, Rohrmann S, Schmid S, Guth U. Overweight, obesity, and breast cancer screening: results from the 2012 Swiss Health Survey. Eur J Cancer Prev. 2015 Mar 19. [Epub ahead of print].
49. Lu Q, Nakmura J, Savinov A, Yue W, Weisz J, Dabbs DJ, et al. Expression of aromatase protein and messenger ribonucleic acid in tumor epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 1996;137:3061-8.
50. Ioannides SJ, Barlow PL, Elwood JM, Porter D. Effect of obesity on aromatase inhibitor efficacy in postmenopausal, hormone receptor-positive breast cancer: a systematic review. Breast Cancer Res Treat 2014; 147:237-48.
51. Docanto MM, Ham S, Corbould A, Brown KA. Obesity-associated inflammatory cytokines and prostaglandin E2 stimulate glucose transporter mRNA expression and glucose uptake in primary human adipose stromal Cells. J Interferon & Cytokine Res 2015;35:600-5.
52. Berger C, Qian Y, Chen X. The p53-estrogen receptor loop in cancer. Curr Mol Med 2013;13:1229-40.
53. Duong V, Boulle N, Daujat S, Chauvet J, Bonnet S, Neel H, et al. Differential regulation of estrogen receptor alpha turnover and transactivation by Mdm2 and stress-inducing agents. Cancer Res 2007;67:5513-21.
54. Haslam SZ, Nummy KA. The ontogeny and cellular distribution of estrogen receptors in normal mouse mammary gland. J Steroid Biochem Mol Biol 1992;42:589-95.
55. Knower KC, Chand AL, Eriksson N, Takagi K, Miki Y, Sasano H, et al. Distinct nuclear receptor expression in stroma adjacent to breast tumors. Breast Cancer Res Treat 2013;142:211-23.
56. Booth ME, Hanby AM, Speirs V. Steroid hormone receptor expression in breast cancer stroma. Breast Cancer Res Treat 2014;143:605-7.
57. Hong B, van den Heuvel AP, Prabhu VV, Zhang S, El-Deiry WS. Targeting tumor suppressor p53 for cancer therapy: strategies, challenges and opportunities. Curr Drug Targets 2014;15:80-9.
58. Warso MA, Richards JM, Mehta D, Christov K, Schaeffer C, Rae Bressler L, et al. A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours. Br J Cancer 2013;108: 1061-70.
59. Grinkevich VV, Nikulenkov F, Shi Y, Enge M, Bao W, Maljukova A, et al. Ablation of key oncogenic pathways by RITA-reactivated p53is required for efficient apoptosis. Cancer Cell 2009;15:441-53.
60. Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H. RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death & Dis 2014;5:e1318.
61. Choi EM, Heo JI, Oh JY, Kim YM, Ha KS, Kim JI, et al. COX-2 regulates p53 activity and inhibits DNA damage-induced apoptosis. Biochem Biophys Res Commu 2005;328:1107-12.
62. Ichikawa A, Ando J, Suda K. G1 arrest and expression of cyclin-dependent kinase inhibitors in tamoxifen-treated MCF-7 human breast cancer cells. Human Cell 2008;21:28-37.
63. Thiantanawat A, Long BJ, Brodie AM. Signaling pathways of apoptosis activated by aromatase inhibitors and antiestrogens. Cancer Res 2003; 63:8037-50.
64. Fitzgibbons PL, Page DL, Weaver D, Thor AD, Allred DC, Clark GM, et al. Prognostic factors in breast cancer. College of American Pathologists Consensus Statement 1999. Arch Pathol Lab Med 2000;124:966-78.
65. Ellis MJ, Ding L, Shen D, Luo J, Suman VJ, Wallis JW, et al. Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 2012;486:353-60.
66. Yamamoto M, Hosoda M, Nakano K, Jia S, Hatanaka KC, Takakuwa E, et al. p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci 2014;105:81-8.
67. Jia XQ, Hong Q, Cheng JY, Li JW, Wang YJ, Mo M, et al. Accumulation of p53 is prognostic for aromatase inhibitor resistance in early-stage post-menopausal patients with ER-positive breast cancer. OncoTargets Ther 2015;8:549-55.